Collegium Pharmaceutical
COLL
24.72
-0.49
-1.94%
Collegium Pharmaceutical
US · COLL
#3535 by market cap
Listed 2015
24.72
-0.49
-1.94%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 24 in the most recent period (2026/Q3).
- Total institutional ownership rose 6.6 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 132.02% +6.55pp
- Institutions
- 320 -24
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund99.43%
Hedge Fund24.15%
Public Company5.43%
Individual/Insider1.17%
Government Pension Fund1.07%
Private Company0.84%
Family Office/Trust0.41%
Insurance Company0.38%
Bank/Investment Bank0.16%
Top holders as of 2026-09-30
BlackRock
17.53% · 5.45M sh
Millennium Management LLC
7.73% · 2.40M sh
Janus Henderson Group plc
6.91% · 2.15M sh
State Street Global Advisors
5.70% · 1.77M sh
Fuller & Thaler Asset Management, Inc.
5.25% · 1.63M sh
Principal Global Investors, LLC
4.87% · 1.51M sh
Renaissance Technologies Corp.
4.53% · 1.41M sh
MFS Investment Management
4.52% · 1.41M sh
Vanguard Capital Management, LLC
4.43% · 1.38M sh
Eventide Asset Management, LLC
4.38% · 1.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 30 sells
| Name | Role | Stake |
|---|---|---|
| Colleen Tupper | Chief Financial Officer | 0.20% |
| John Fallon | Former Independent Director | 0.18% |
| Gino Santini | Independent Chairperson | 0.14% |
| Michael Heffernan | Former Co-Founder & Chairman | 0.14% |
| John Freund | Independent Director | 0.14% |
| Vikram Karnani | Chief Executive Officer | 0.13% |
| Thomas Smith | Chief Medical Officer | 0.12% |
| Rita Balice-Gordon | Independent Director | 0.07% |
| Gwen A. Melincoff | Former Independent Director | 0.04% |
| Nancy Lurker | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Scott Dreyer | Former Executive Vice President | Intent to Sell (Form 144) | -27,419 | $22.00 |
| 2026-07-16 | John Fallon | Former Independent Director | Intent to Sell (Form 144) | -13,920 | $35.73 |
| 2026-07-14 | John Fallon | Former Independent Director | Intent to Sell (Form 144) | -8,095 | $36.32 |
| 2026-06-07 | Gino Santini | Independent Chairperson | Derivative Exercise and Retained | +8,700 | $16.49 |
| 2026-05-17 | John Freund | Independent Director | Open Market Disposition | -20 | $34.05 |
| 2026-05-14 | John Freund | Independent Director | Derivative Exercise and Sale | -4,127 | $16.49–34.54 |
| 2026-05-14 | John Freund | Independent Director | Derivative Exercise and Retained | +4,573 | $16.49 |
| 2026-05-13 | John Freund | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Nancy Lurker | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Garen Bohlin | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Gino Santini | Independent Chairperson | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Carlos Paya | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Rita Balice-Gordon | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Michael Donovan | Independent Director | Other Acquisition | +17,482 | -- |
| 2026-05-12 | Nancy Lurker | Independent Director | Open Market Disposition | -4,500 | $35.97 |
| 2026-05-10 | Garen Bohlin | Independent Director | Derivative Exercise and Sale | -8,700 | $16.49–37.18 |
| 2026-03-17 | David Dieter | General Counsel | Automatic Disposition | -13,976 | $34.92 |
| 2026-03-16 | David Dieter | General Counsel | Sale to Issuer | -8,840 | $35.72 |
| 2026-03-08 | David Dieter | General Counsel | Automatic Disposition | -6,224 | $36.65 |
| 2026-03-02 | Scott Dreyer | Former Executive Vice President | Automatic Disposition | -49,976 | $40.36–40.99 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Collegium Pharmaceutical discussion 0 comments